Corporate ActionJul 20, 2026, 08:22 AM
Ascentage Pharma Proposes $200M At-The-Market Offering
AI Summary
Ascentage Pharma Group International announced a proposed At-The-Market (ATM) offering program to sell up to $200 million of its American Depositary Shares (ADSs). The company filed an automatic shelf registration statement on Form F-3 with the U.S. SEC for this purpose. The net proceeds are intended to fund the commercialization of its drug candidates Olverembatinib and Lisaftoclax, support ongoing clinical trials, and cover working capital and general corporate purposes. The program is subject to obtaining waivers from the Hong Kong Listing Rules, and sales will be conducted on Nasdaq through designated sales agents.
Key Highlights
- Proposed At-The-Market (ATM) offering program for up to $200 million in ADSs.
- Filed an automatic shelf registration statement on Form F-3 with the U.S. SEC.
- ADSs to be sold on Nasdaq through sales agents Citigroup, Deutsche Bank, and BTIG.
- Net proceeds to fund commercialization of Olverembatinib and Lisaftoclax, and ongoing clinical trials.
- Proceeds also for working capital, general corporate purposes, and improving ADS trading liquidity.
- Application for waivers from Hong Kong Listing Rules is pending.
- Sales will not occur during blackout periods or with material non-public information.
- Offering utilizes the General Mandate granted by shareholders on May 20, 2026.
Price Impact
More from AAPG